Skip to main content
null
prnano
  • Menu
  • Articles
    • Case study
    • Communication
    • Editorial
    • Editorial Policies
    • Expression of concern
    • Letters to the Editor
    • Perspective, Opinion, or Discussion
    • Research Article
    • Review
    • Technical Note
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • The Rising Talents List
  • Journal Policies
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

https://precisionnanomedicine.com/feed
Research Article
Vol. 1, Issue 3, 2018September 25, 2018 EDT

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin

Adam Friedman, Kenny Ye, Alicia Rodriguez-Gabin, Joshua Nosanchuk, Joel Friedman, Alan Alfieri, Mahantesh Navanti, Angelo Landriscina, Jamie Rosen, David Schairer, Joy Makdisi, Brandon Adler, Aimee Krausz, Hayley McDaid,
experimental therapeuticsnanoparticlestriple-negative breast cancerdoxorubicindrug resistance
Copyright Logoccby-nc-sa-4.0 • https://doi.org/10.33218/prnano1(3).181029.1
prnano
Friedman, Adam, Kenny Ye, Alicia Rodriguez-Gabin, Joshua Nosanchuk, Joel Friedman, Alan Alfieri, Mahantesh Navanti, et al. 2018. “Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin.” Precision Nanomedicine 1 (3): 173–82. https:/​/​doi.org/​10.33218/​prnano1(3).181029.1.
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system